AVITA Medical (ASX: AVH) Raises Revenue Forecast as Cash Burn Falls. Can It Reach Breakeven in 2026?

AVITA Medical Inc. (ASX: AVH) has delivered 53% quarterly revenue growth, improved margins and sharply reduced cash consumption, strengthening its prospects of reaching cash flow breakeven before the end of 2026.

The wound-care specialist has also raised its annual revenue guidance and secured additional debt funding. However, with substantial borrowings and continuing losses, the critical question is whether commercial momentum can translate into sustainable cash generation.

Key Numbers

• Quarterly revenue: US$26.1 million for Q3 2026, up 53% year-on-year and 20% sequentially.
• Gross margin: 84.0%, compared with 81.3% a year earlier.
• Net loss: US$6.2 million, narrowing from US$13.2 million in Q3 2025.
• Net cash consumption: Approximately US$0.6 million during Q3, down from US$3.2 million in Q2.
• 2026 revenue guidance: Raised to US$92 million–US$94 million from US$86 million–US$89 million.

The Latest Development: Revenue Growth Strengthens the Financial Outlook

AVITA's third-quarter results, released on 6 November 2026 Australian time, demonstrate accelerating demand for its wound-care products.

Its flagship RECELL platform generated US revenue of US$22.4 million, approximately 20% higher than the previous quarter.

RECELL uses a patient's own skin cells to support wound healing, potentially reducing donor skin requirements for burns and traumatic injuries.

Meanwhile, Cohealyx generated US$2.1 million in revenue, increasing approximately 21% sequentially as hospital adoption expanded.

Importantly, AVITA achieved the US$85 million trailing 12-month revenue milestone required to access another US$10 million under its Perceptive Advisors credit facility.

The company drew this additional funding after quarter-end, bringing total facility borrowings to US$60 million.

Management also concluded that substantial doubt about AVITA's ability to continue as a going concern had been alleviated, reflecting improved liquidity and operating performance.

What Stands Out to Us

AVITA's improving operating leverage is particularly encouraging.

Quarterly gross profit reached approximately US$21.9 million against operating expenses of US$24.6 million, leaving an operating loss of approximately US$2.7 million.

Operating expenses remained broadly unchanged from Q2 despite strong revenue growth, suggesting improving cost efficiency.

However, cash flow requires closer examination.

Although quarterly net cash consumption declined to US$0.6 million, the company remains loss-making and must demonstrate that lower cash usage is sustainable.

AVITA held approximately US$10.5 million in cash, cash equivalents and marketable securities at 30 September, before receiving the additional debt funding.

Its strong gross margins support the commercial opportunity, but profitability remains unproven.

With substantial debt and continuing losses, an earnings-based valuation remains difficult to establish without clearer evidence of sustainable cash generation.

What the Company Is Doing Now

AVITA is expanding its wound-care portfolio through RECELL, Cohealyx and PermeaDerm while strengthening hospital relationships.

Its PermeaDerm clinical study demonstrated comparable wound-healing outcomes to allograft, with reported product-cost savings of 70% and preparation-time reductions of 95.7%.

A separate announcement released on 5 November 2026 US time confirmed that Medicare authorities had finalised national physician payment values and simplified billing arrangements for RECELL procedures.

Effective 1 January 2027, four billing codes will replace eight, while nationally published physician valuations will replace regional arrangements.

These changes could improve reimbursement predictability and reduce administrative complexity, potentially supporting broader clinical adoption. However, they do not guarantee higher product sales.

Insight: Is AVITA's Financial Turning Point Finally Emerging?

We think AVITA's latest results represent genuine commercial progress, supported by accelerating RECELL sales, improving margins and greater operating efficiency. Its proprietary technology and established clinical applications provide differentiation in specialised wound care. However, US$60 million in facility borrowings, continuing operating losses and potential shareholder dilution remain important constraints. The improved funding position provides breathing room but does not eliminate financial risk. Sustained positive operating cash flow, rather than another quarter of revenue growth alone, would provide stronger evidence that AVITA's business model can deliver lasting financial value.

What Happens Next?

AVITA expects fourth-quarter revenue of US$24.9 million–US$26.9 million and has reaffirmed its target of achieving cash flow breakeven during Q4 2026.

That remains a management expectation rather than an achieved milestone.

The introduction of revised Medicare reimbursement arrangements in January 2027 provides another potential catalyst.

For shareholders, the decisive indicators will be sustained revenue growth, operating cash generation and the company's ability to manage its debt obligations without requiring significant additional capital.

AVITA has demonstrated improving commercial momentum. Its next challenge is proving that growth can consistently fund the business.